{
    "ticker": "RVYL",
    "name": "Revelation Biosciences, Inc.",
    "description": "Revelation Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for severe allergic responses and other immune-related conditions. Founded in 2015, Revelation aims to revolutionize the treatment of allergies and immune disorders through its proprietary technologies and research. The company is particularly known for its lead product candidate, RVL-1201, which is being developed to treat allergic rhinitis and other allergic conditions. The unique mechanism of action of RVL-1201 targets the underlying causes of allergies, potentially providing a more effective and safer alternative to existing treatments. Revelation\u2019s commitment to advancing science is reflected in its robust pipeline and collaborations with leading research institutions. The company is dedicated to improving patient outcomes and enhancing the quality of life for individuals suffering from allergies and immune system disorders. With a strong focus on research and development, Revelation is positioned at the forefront of the biotechnology sector, aiming to bring innovative solutions to the market that address significant unmet medical needs.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2015",
    "website": "https://www.revelationbio.com",
    "ceo": "James A. Barlow",
    "social_media": {
        "twitter": "https://twitter.com/revelationbio",
        "linkedin": "https://www.linkedin.com/company/revelation-biosciences/"
    },
    "investor_relations": "https://www.revelationbio.com/investors",
    "key_executives": [
        {
            "name": "James A. Barlow",
            "position": "CEO"
        },
        {
            "name": "Joseph A. Kearney",
            "position": "Chief Scientific Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "RVL-1201"
            ]
        }
    ],
    "seo": {
        "meta_title": "Revelation Biosciences, Inc. | Innovating Allergy Therapies",
        "meta_description": "Revelation Biosciences, Inc. is advancing the treatment of allergies and immune-related conditions with innovative therapies. Explore our pipeline and mission.",
        "keywords": [
            "Revelation Biosciences",
            "Biotechnology",
            "Allergy Treatment",
            "Immunology",
            "RVL-1201"
        ]
    },
    "faq": [
        {
            "question": "What is Revelation Biosciences known for?",
            "answer": "Revelation Biosciences is known for developing innovative therapies for severe allergies and immune-related conditions."
        },
        {
            "question": "Who is the CEO of Revelation Biosciences?",
            "answer": "James A. Barlow is the CEO of Revelation Biosciences, Inc."
        },
        {
            "question": "Where is Revelation Biosciences headquartered?",
            "answer": "Revelation Biosciences is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is the main product of Revelation Biosciences?",
            "answer": "The main product is RVL-1201, which is being developed for treating allergic rhinitis."
        },
        {
            "question": "When was Revelation Biosciences founded?",
            "answer": "Revelation Biosciences was founded in 2015."
        }
    ],
    "competitors": [
        "ALNY",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "MRNA",
        "GILD"
    ]
}